Service for the support of the European orphan medicine market
EuOrphan aimed at validating a web service for the distribution of a complete set of information concerning medicines (orphan drugs) designated and/or commercialized both in EU and non EU countries for the treatment of rare diseases.
THE PROJECT
The Euorphan project thus supported the European Legislation which came into force across the European Union in April 2000, to encourage commercial companies (with particular reference to the SMEs) to bring orphan medicines to the market and to support the availability of orphan drugs to EU patients.
CONSORTIUM
A consolidated research group with a renowned academic and industrial profile.
- Consorzio per Valutazioni Biologiche e Farmacologiche (IT)
- Softeco Sismat S.p.A. (IT)
- Istituto Superiore Sanità (IT)
- Fundación para la Cooperación y Salud Internacional Carlos III, CISATER Centre (ES)
- Universidad de Barcelona, Facultad de Farmacia, Departamento de Farmacia y tecnologia Farmacéutica (ES)
- Karolinska Institutet, Department of Woman and Child Health (SE)
- Fondazione Italiana Leonardo Giambrone per la guarigione della thalassemia (IT)
- SC Sviluppo Chimica S.p.A. (IT)
- Scuola Europea di Medicina Generale (IT)
- Società di Scienze Farmcologiche Applicate (IT)
- Vilnius University, Institute of Oncology (LT)
- Confederation of European Specialists in Paediatrics (BE)
- UNIAMO, Federazione Italiana Malattie Rare (IT)
SYNOPSIS
COORDINATOR
Consorzio per Valutazioni Biologiche e Farmacologiche (IT)
PROGRAM
eTEN
START DATE
January 2005
DURATION
18 months
FLYER
GALLERY
